N-[2-[2-[2-(2-propan-2-yloxyethoxy)ethoxy]ethoxy]ethyl]propan-2-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[2-[2-[2-(2-propan-2-yloxyethoxy)ethoxy]ethoxy]ethyl]propan-2-amine
• 化学式: C₁₄H₃₁NO₄
• 分子量: 277.4
• InChiKey: PRFMISBRMYJFDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  19
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME
  申请人：Coferon, Inc.

  公开号：US20140243322A1

  公开（公告）日：2014-08-28

  Described herein are compounds capable of modulating one or more biomolecules substantially simultaneously, e.g., modulating two or more binding domains (e.g., bromodomains) on a protein or on different proteins.

  本文描述了一些化合物，能够在实质上同时调节一个或多个生物分子，例如，在蛋白质上或不同蛋白质上调节两个或更多结合域（例如溴结构域）。
• IRAK degraders and uses thereof
  申请人：Kymera Therapeutics, Inc.

  公开号：US11318205B1

  公开（公告）日：2022-05-03

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE
  申请人：Yale University

  公开号：US20200121684A1

  公开（公告）日：2020-04-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Burton's Tyrosine Kinase (BTK). In particular, the present disclosure is directed to bifunctional compounds. One end of a bifunctional compound includes a Von Hippel-Lindau, Cereblon, Inhibitors of Apotosis Proteins, or Mouse Double-Minute Homolog 2 ligand that binds to the respective E3 ubiquitin ligase. The other end of a bifunctional compound includes a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein can be treated or prevented with compounds and compositions of the present disclosure.
• PROTEIN DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20210002296A1

  公开（公告）日：2021-01-07

  The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.
• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20210228562A1

  公开（公告）日：2021-07-29

  The present invention provides compounds, compositions thereof, and methods of using the same.